Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of NK.


Clinical Trial Description

Neurotrophic keratopathy (NK) is a degenerative corneal disease that occurs as a result of partial or total impairment of trigeminal innervation. The resulting loss of corneal sensitivity (anesthesia) leads to a reduction in lacrimation and a decline in status, metabolism, and mitosis of corneal epithelial cells. Previous studies (physician-sponsored studies) used to treat to nine patients with NK, six of whom had discrete geographic, non-healing lesions, and three of whom had punctate lesions and the study result reported. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02600429
Study type Interventional
Source ReGenTree, LLC
Contact
Status Terminated
Phase Phase 3
Start date September 17, 2015
Completion date March 9, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04604834 - Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy N/A
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Completed NCT04293549 - An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops
Completed NCT04957758 - Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy Phase 2
Terminated NCT03084861 - A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy Phase 1/Phase 2
Active, not recruiting NCT06411145 - Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis Phase 4
Recruiting NCT05555589 - Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 Phase 3
Not yet recruiting NCT06331910 - Efficacy and Safety of Topical Insulin for Neurotrophic Corneal Ulcers Phase 4